268 related articles for article (PubMed ID: 17471009)
1. [Phosphate binder up to date].
Shigematsu T; Sakaguchi T; Orita H
Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the phosphate binder, lanthanum carbonate.
Damment SJ
Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
4. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Hanba Y; Masumoto A; Moribata M; Shigemathu T
Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
[TBL] [Abstract][Full Text] [Related]
5. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
Koiwa F; Sato Y
Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
[TBL] [Abstract][Full Text] [Related]
6. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
7. [Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
Skaguchi T; Shigematsu T
Clin Calcium; 2009 Jun; 19(6):844-51. PubMed ID: 19483280
[TBL] [Abstract][Full Text] [Related]
8. The clinical management of hyperphosphatemia.
Ritz E
J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
[TBL] [Abstract][Full Text] [Related]
9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
11. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Mohammed I; Hutchison AJ
J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
[TBL] [Abstract][Full Text] [Related]
13. Improving phosphate-binder therapy as a way forward.
Hutchison AJ
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
15. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
16. [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].
Bolasco P
G Ital Nefrol; 2011; 28(4):357. PubMed ID: 21809303
[No Abstract] [Full Text] [Related]
17. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
[No Abstract] [Full Text] [Related]
18. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binder usage in kidney failure patients.
Bleyer AJ
Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
[TBL] [Abstract][Full Text] [Related]
20. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
Curran MP; Robinson DM
Drugs; 2009 Nov; 69(16):2329-49. PubMed ID: 19852531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
